Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease".
Press Release Feb 06 2026
Filed with NSE · · 4 pages · English
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Feb 04 2026
- Press Release Jan 23 2026
- Press Release Jan 22 2026
- Press Release Jan 15 2026
- Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
Later from Zydus Lifesciences
- Press Release Feb 09 2026
- Press Release 10-02-2026 NewspaperPublication10022026
- Zydus Lifesciences Limited Press Release Feb 14 2026
- Zydus Lifesciences Limited Press Release Feb 17 2026
- Press Release Feb 18 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences